Lupin gets USFDA approval for diabetes drug

3 February 2012 : Drug firm Lupin has received approval from the US health regulator for its Metformin Hydrochloride Extended Release tablets, used in treating diabetes. The company's US-based subsidiary Lupin Pharmaceuticals Inc has received tentative approval from US Food and Drug Administration (USFDA) for Metformin tablets in strengths of 500 mg and 1,000 mg.

Lupin's Metformin HCl ER Tablets are the AB-rated generic equivalent of Santarus Inc's Glumetza HCl ER Tablets. Shares of Lupin closed higher by 0.77 per cent at Rs 470.60 on the BSE. Metformin HCl ER tablets is a biguanide and is indicated as an supplement to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Source: Economic Times